SCHEMBL30624366

SCHEMBL30624366

Cc1cc(C#N)cnc1C

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.44
EGLN2 Q96KS0 6/20 0.43
ALDH1A1 P00352 3/20 0.40
KDM4E B2RXH2 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
LMNA P02545 1/20 0.40
GAA P10253 1/20 0.40
HPGDS O60760 2/20 0.40
RAF1 P04049 1/20 0.38
CYP2A6 P11509 2/20 0.36
CYP11B1 P15538 1/20 0.36
CYP11B2 P19099 1/20 0.36
LRRK2 Q5S007 1/20 0.35
GRM5 P41594 1/20 0.35
PTGER4 P35408 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL846133 1.00 HTT (0.44) HTTEGLN2ALDH1A1KDM4EL3MBTL1
SCHEMBL12941448 0.80 HTT (0.42) HTTEGLN2ALDH1A1KDM4EL3MBTL1
SCHEMBL22066216 0.80 HTT (0.42) HTTEGLN2ALDH1A1KDM4EL3MBTL1
SCHEMBL2951427 0.79 KDM4E (0.39) HTTEGLN2ALDH1A1KDM4EL3MBTL1
SCHEMBL619851 0.78 HTT (0.41) HTTEGLN2ALDH1A1KDM4EL3MBTL1
SCHEMBL11619514 0.78 HTT (0.50) HTTEGLN2ALDH1A1KDM4EL3MBTL1
SCHEMBL22889834 0.78 HTT (0.60) HTTEGLN2ALDH1A1KDM4EL3MBTL1
SCHEMBL31200301 0.78 HTT (0.60) HTTEGLN2ALDH1A1KDM4EL3MBTL1
SCHEMBL7940220 0.78 CHRNB2 (0.42) HTTEGLN2ALDH1A1KDM4EL3MBTL1
SCHEMBL7935603 0.78 HTT (0.41) HTTEGLN2ALDH1A1KDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250206757-A1 5,8-DIHYDRO-1,7-NAPHTHYRIDINE DERIVATIVES AS GLP-1 AGONISTS FOR THE TREATMENT OF DIABETES GASHERBRUM BIO, INC. 2025-06-26 US disclosed
EP-4496797-A1 5,8-DIHYDRO-1,7-NAPHTHYRIDINE DERIVATIVES AS GLP-1 AGONISTS FOR THE TREATMENT OF DIABETES Gasherbrum Bio, Inc. (US) 2025-01-29 EP disclosed
WO-2023179542-A1 5,8-DIHYDRO-1,7-NAPHTHYRIDINE DERIVATIVES AS GLP-1 AGONISTS FOR THE TREATMENT OF DIABETES GASHERBRUM BIO , INC. (US) 2023-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250206757-A1 5,8-DIHYDRO-1,7-NAPHTHYRIDINE DERIVATIVES AS GLP-1 AGONISTS FOR THE TREATMENT OF DIABETES GLP1R, IAPP, GPR119 HTT 794/4885EGLN2 2342/4885ALDH1A1 1791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.